The concept of idiotypic vaccination against factor VIII inhibitors in haemophilia A.
Idiotypic vaccination has proven successful in several animal models and human trials. Here we suggest that the expression of cross-reactive idiotypes on factor VIII (FVIII) inhibitors of patients with haemophilia A, patients with anti-FVIII autoimmune disease and natural anti-FVIII antibodies of healthy individuals, together with the ability of anti-idiotypic reagents to neutralize anti-FVIII antibodies, provides a rationale for designing a vaccine strategy aimed at preventing the occurrence of or suppressing inhibitors, based on the induction of protective anti-idiotypes. Here we discuss the rationale supporting the concept of using idiotypic vaccination to prevent the occurrence of FVIII inhibitors in patients with haemophilia A.
Lacroix-Desmazes
S
S
INSERM U 430 and Université Pierre et Marie Curie, Hôpital Broussais, Paris, France.
Bayry
J
J
Misra
N
N
Kaveri
S V
SV
Kazatchkine
M D
MD
D000906:Antibodies / Q000276:immunology*; D000917:Antibody Formation; D005169:Factor VIII / Q000037:antagonists & inhibitors / Q000276:immunology*; D006467:Hemophilia A / Q000276:immunology / Q000517:prevention & control*; D006801:Humans; D014611:Vaccination; D014612:Vaccines / Q000276:immunology*
D000906:Antibodies; D014612:Vaccines; D005169:Factor VIII